       Document 0560
 DOCN  M9630560
 TI    Working toward a common currency: is standardization of
       cost-effectiveness analysis possible?
 DT    9603
 AU    Luce BR; MEDTAP International, Inc., Arlington, Virginia 22201, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S19-22.
       Unique Identifier : AIDSLINE MED/96075585
 AB    The field of cost-effectiveness has been quietly evolving for several
       decades. However, concerns and controversies have recently surfaced
       regarding the lack of standardization with which cost-effectiveness
       analyses are performed. This attention is due to the increasing use of
       the technique in rationing health care, setting price and/or
       reimbursement levels, adopting new technologies, and marketing
       pharmaceutical products. Is standardization possible while the field is
       still developing? This article explores possible answers to this
       question and reviews worldwide efforts aimed at the development of
       standardized guidelines for cost-effectiveness analysis.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/ECONOMICS  Antiviral
       Agents/ECONOMICS  Clinical Trials  Cost-Benefit Analysis/*STANDARDS
       Economics, Pharmaceutical/STANDARDS  Guidelines  Human  Models,
       Theoretical  Prospective Studies  Quality of Life  Research Design
       Retrospective Studies  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

